Company Overview of Aptalis Pharma Inc.
Aptalis Pharma Inc., a specialty pharmaceutical company, develops therapies cystic fibrosis and gastrointestinal disorders primarily in the United States, the European Union, and Canada. The company manufactures and commercializes various pharmaceutical products, including ZENPEP, ULTRASE, and VIOKASE products for the treatment of exocrine pancreatic insufficiency (EPI); PANZYTRAT for use in the treatment of EPI and pancreatic enzyme deficiency; CANASA for the treatment of ulcerative proctitis; and SALOFALK for the treatment of inflammatory bowel diseases, such as ulcerative colitis, ulcerative proctitis, and Crohn’s disease. It also offers CARAFATE and SULCRATE product lines for the treatme...
22 Inverness Center Parkway
Birmingham, AL 35242
Founded in 2007
Key Executives for Aptalis Pharma Inc.
President of International Specialty Pharmaceuticals
President of Pharmaceutical Technologies
Compensation as of Fiscal Year 2013.
Aptalis Pharma Inc. Key Developments
Aptalis Pharma Reportedly Mulls IPO
Oct 23 13
Aptalis Pharma Inc. is understood to have appointed underwriters for an initial public offering (IPO) after efforts to sell the company failed, according to people familiar with the matter. Goldman Sachs Group Inc and JPMorgan Chase & Co will lead the offering, which might not happen until 2014, the people added on condition of anonymity because the discussions are private. TPG Capital, L.P., Aptalis, Goldman Sachs and JPMorgan did not immediately respond to requests for comment to Reuters.
Aptalis Pharma Presents at BioNJ CEO Summit 2013, Oct-04-2013 11:15 AM
Oct 4 13
Aptalis Pharma Presents at BioNJ CEO Summit 2013, Oct-04-2013 11:15 AM. Venue: Bridgewater Marriott, Bridgewater, New Jersey, United States. Speakers: John Fraher, President.
Aptalis Pharma, US Inc. Announces Launch of PYLERA 10 Day Therapy PAK in the U.S
Sep 3 13
Aptalis Pharma, US Inc. announces the launch of PYLERA(R) 10 Day Therapy PAK in the U.S. PYLERA(R) capsules (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride), in combination with omeprazole, is indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. PYLERA is the only branded treatment option available that does not contain clarithromycin, a macrolide antibiotic. Utilization of macrolide antibiotics are believed to contribute to the growing rate of clarithromycin-resistant H. pylori. With the 10 Day Therapy PAK, physicians now have a PYLERA option that leverages innovative 3-in-1 capsule technology in blister packaging for convenient administration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|